Open-label randomized control trial of hydroxychloroquine in patients with moderate to severe coronavirus disease 2019 infection

BACKGROUND: At onset of coronavirus disease 2019 (COVID-19) pandemic, hydroxychloroquine (HCQ) was repurposed for treatment of patients based on reports that it had in vitro activity. The aim of this study was to find out if HCQ reduces number of days of hospitalization when given to patients with m...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Salil, Dixit, Prashant Kumar, Ghana, Parthasarathi, Abhisheka, Kumar, Khurana, Harshit, Jha, Vijoy Kumar, Mahapatra, Debasish, Goel, Jitesh, Ahmed, Safia, Varadaraj, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313076/
https://www.ncbi.nlm.nih.gov/pubmed/34334898
http://dx.doi.org/10.1016/j.mjafi.2021.02.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313076/
https://www.ncbi.nlm.nih.gov/pubmed/34334898
http://dx.doi.org/10.1016/j.mjafi.2021.02.007

Ejemplares similares